Oligonucleotide Therapeutics Industry Research Report 2025

Summary


Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

According to APO Research, The global Oligonucleotide Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Oligonucleotide Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Oligonucleotide Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Oligonucleotide Therapeutics include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Oligonucleotide Therapeutics Segment by Company

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Oligonucleotide Therapeutics Segment by Type

Antisense Oligonucleotide
Aptamer
Other
Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Oligonucleotide Therapeutics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oligonucleotide Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Oligonucleotide Therapeutics by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Antisense Oligonucleotide
2.2.3 Aptamer
2.2.4 Other
2.3 Oligonucleotide Therapeutics by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Neuromuscular Diseases
2.3.3 ATTR
2.3.4 Hepatic VOD
2.3.5 Other
2.4 Assumptions and Limitations
3 Oligonucleotide Therapeutics Breakdown Data by Type
3.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2026-2031)
4 Oligonucleotide Therapeutics Breakdown Data by Application
4.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Oligonucleotide Therapeutics Market Perspective (2020-2031)
5.2 Global Oligonucleotide Therapeutics Growth Trends by Region
5.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2020-2025)
5.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2026-2031)
5.3 Oligonucleotide Therapeutics Market Dynamics
5.3.1 Oligonucleotide Therapeutics Industry Trends
5.3.2 Oligonucleotide Therapeutics Market Drivers
5.3.3 Oligonucleotide Therapeutics Market Challenges
5.3.4 Oligonucleotide Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Oligonucleotide Therapeutics Players by Revenue
6.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2020-2025)
6.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2020-2025)
6.2 Global Oligonucleotide Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Oligonucleotide Therapeutics Head Office and Area Served
6.4 Global Oligonucleotide Therapeutics Players, Product Type & Application
6.5 Global Oligonucleotide Therapeutics Manufacturers Established Date
6.6 Global Oligonucleotide Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Oligonucleotide Therapeutics Market Size (2020-2031)
7.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Oligonucleotide Therapeutics Market Size by Country (2020-2025)
7.4 North America Oligonucleotide Therapeutics Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Oligonucleotide Therapeutics Market Size (2020-2031)
8.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Oligonucleotide Therapeutics Market Size by Country (2020-2025)
8.4 Europe Oligonucleotide Therapeutics Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2020-2031)
9.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2020-2025)
9.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Oligonucleotide Therapeutics Market Size (2020-2031)
10.2 South America Oligonucleotide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Oligonucleotide Therapeutics Market Size by Country (2020-2025)
10.4 South America Oligonucleotide Therapeutics Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2020-2031)
11.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2020-2025)
11.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Biogen
12.1.1 Biogen Company Information
12.1.2 Biogen Business Overview
12.1.3 Biogen Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
12.1.5 Biogen Recent Developments
12.2 Sarepta Therapeutics
12.2.1 Sarepta Therapeutics Company Information
12.2.2 Sarepta Therapeutics Business Overview
12.2.3 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
12.2.5 Sarepta Therapeutics Recent Developments
12.3 Jazz Pharmaceuticals
12.3.1 Jazz Pharmaceuticals Company Information
12.3.2 Jazz Pharmaceuticals Business Overview
12.3.3 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
12.3.5 Jazz Pharmaceuticals Recent Developments
12.4 Bausch & Lomb
12.4.1 Bausch & Lomb Company Information
12.4.2 Bausch & Lomb Business Overview
12.4.3 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
12.4.5 Bausch & Lomb Recent Developments
12.5 Alnylam Pharmaceuticals
12.5.1 Alnylam Pharmaceuticals Company Information
12.5.2 Alnylam Pharmaceuticals Business Overview
12.5.3 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
12.5.5 Alnylam Pharmaceuticals Recent Developments
12.6 Dynavax Technologies
12.6.1 Dynavax Technologies Company Information
12.6.2 Dynavax Technologies Business Overview
12.6.3 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
12.6.5 Dynavax Technologies Recent Developments
12.7 Kastle therapeutics
12.7.1 Kastle therapeutics Company Information
12.7.2 Kastle therapeutics Business Overview
12.7.3 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
12.7.5 Kastle therapeutics Recent Developments
12.8 Akcea Therapeutics
12.8.1 Akcea Therapeutics Company Information
12.8.2 Akcea Therapeutics Business Overview
12.8.3 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2020-2025)
12.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
12.8.5 Akcea Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings